Pleural effusion

Pleural Dynamics Receives FDA 510(k) Clearance for its Novel ACES™ Automatic Continuous Effusion Shunt System

Retrieved on: 
Thursday, October 19, 2023
FDA, Health, Medical Devices, Pleurodesis, Critical Care Medicine (journal), Pleural cavity, Pleural effusion, Interventional radiology, Drainage, Abdomen, Patient, Food and Drug Administration, Food, Hospital, Medical device

Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ACES™ Automatic Continuous Effusion Shunt System.

Key Points: 
  • Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ACES™ Automatic Continuous Effusion Shunt System.
  • Pleural Dynamics’ patented ACES™ System addresses these shortcomings1 with its’ one-piece, fully implanted system that can be placed during a short hospital stay.
  • With this FDA 510(k) clearance, Pleural Dynamics will begin real-world clinical use of the ACES™ System with select hospitals and health systems.
  • Pleural Dynamics’ latest technology will play a vital role in improving the lives of patients with intractable pleural effusion.

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Annual general meeting, Constipation, JCO, Fatal, Arrhythmia, Joint Planning and Development Office, NYSE, Lung cancer, Food, Cetuximab, Myocardial infarction, Memorial Sloan Kettering Cancer Center, IRC, Plasma, Vomiting, NSCLC, Bleeding, Cough, Anemia, BRAF, Pfizer, ORR, Inc., Society, American Society of Clinical Oncology, Mutation, CRC, Disease, Diarrhea, Abdominal pain, Visual impairment, DSM-IV codes, Nausea, Rash, Periodic breathing, Journal, Fatigue, DOR, Pneumonia, Intracranial hemorrhage, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, MSK, ASCO, Pleural effusion, Edema, Patient, PFE, Risk, Pharmaceutical industry

“Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.

Key Points: 
  • “Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.
  • “The PHAROS trial demonstrated that these patients could benefit from BRAFTOVI + MEKTOVI targeted therapy regardless of their prior treatment history.
  • BRAFTOVI + MEKTOVI is also FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • BRAFTOVI is FDA-approved, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Merit Medical Launches the Aspira® Evacuated Drainage Bottle 

Retrieved on: 
Wednesday, September 6, 2023
Heart, Thoracostomy, Hospital, Drainage, Survival, Cancer, Quality of life, MMSI, Pleural effusion, Pain, Health care, Patient, Aspira, Abdomen, Health, Thoracentesis, Ascites, Medical imaging

SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.

Key Points: 
  • SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.
  • The new evacuated drainage bottle is the latest addition to Merit’s drainage portfolio.
  • The bottle also offers convenience with its ease-of-use and advanced design that requires 23% less storage space than the leading drainage bottle on the market.1 To further optimize patient comfort, the Aspira Bottle allows users to control drainage speed, helping to minimize discomfort and pain associated with high vacuum pressure drainage.
  • “The Aspira Bottle is one more way Merit strives to improve patient care, which includes providing the option of at-home care,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO.

ConcertAI's TeraRecon Partners with GLEAMER to Advance Clinical AI Capabilities on the Eureka Clinical AI Platform

Retrieved on: 
Monday, August 14, 2023
CE, Partnership, Pneumothorax, Radiology, Pleural effusion, Patient, Fracture, Algorithm, AI, Cardiology, Elective surgery, FDA, Neurology, Medical device, Medical imaging

CAMBRIDGE, Mass., Aug. 14, 2023 /PRNewswire/ -- Advanced visualization and AI leader TeraRecon, a ConcertAI company, is proud to announce its strategic partnership with GLEAMER, a leading provider of AI solutions for medical imaging. By joining forces, the two companies aim to advance the field of radiology by integrating GLEAMER's BoneView and ChestView solutions into TeraRecon's Eureka Clinical AI Platform.

Key Points: 
  • By joining forces, the two companies aim to advance the field of radiology by integrating GLEAMER's BoneView and ChestView solutions into TeraRecon's Eureka Clinical AI Platform.
  • GLEAMER's BoneView (FDA) and BoneView (CE), which offer AI-powered bone fracture identification, will seamlessly integrate with the Eureka Clinical AI platform.
  • "We are thrilled to partner with GLEAMER and integrate their advanced AI algorithms into the Eureka Clinical AI platform," said Dan McSweeney, President of TeraRecon.
  • Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: https://www.terarecon.com/artificial-intelligence

Hair Loss Drug Can be Deadly to Pets

Retrieved on: 
Wednesday, August 9, 2023
Blood pressure, Hair, Journal of the American Academy of Dermatology, Argyreia nervosa, Vomiting, Minoxidil, Hair loss, Gastrointestinal tract, Hypotension, Dog, Pet, Hypothermia, American Academy, War, Cat, Cyanosis, Human, Animal, Pleural effusion, Poisoning, Lethargy, Water, Child, Periodic breathing, Broadway, Observation, Heart rate, Pulmonary edema, Medical imaging, Birth control

MINNEAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Humans are obsessed with hair. We have entire industries dedicated to growing it, losing it, regrowing it, artificially replacing it, washing it, cutting it, coloring it, shaving it, waxing it, styling it, covering it and photographing it. We even have a smash Broadway musical celebrating it.

Key Points: 
  • Perhaps the biggest holy grail in the hair care industry is a cure for baldness.
  • According to the American Academy of Dermatology, more than 80 million Americans suffer from hair loss.
  • In honor of National Hair Loss Awareness Month in August, the toxicology experts at Pet Poison Helpline want to warn hair-loss medication users how dangerous it can be to pets.
  • "Products like Rogaine®, which contain the medication minoxidil , have helped many people with hair loss," said Dr. Renee Schmid, a senior veterinary toxicologist at Pet Poison Helpline.

Women's World Cup: The epidemic of ACL tears in female soccer players is about more than just biology

Retrieved on: 
Tuesday, August 1, 2023
People, Exercise, Yoga, Hamstring, Male, NCAA, Female, Awareness, Pleural effusion, Knee, Anatomy, Connective tissue, Tears, Season, World, Woman, Research, Brain, Osteoarthritis, Factorization of polynomials, Movement, Pain, Athlete, National Association Medical Staff Services, NCAA Division I men's basketball tournament, Risk, Anterior cruciate ligament, Growth, Health, ACL, Football, Sport, Toy, Glass, Birth control

Over 25 of the world’s top female soccer players are missing the 2023 FIFA Women’s World Cup because of ACL tears, including Canada’s Janine Beckie.

Key Points: 
  • Over 25 of the world’s top female soccer players are missing the 2023 FIFA Women’s World Cup because of ACL tears, including Canada’s Janine Beckie.
  • If we trust the research, we should brace ourselves for two to three ACL tears during the World Cup itself.

Dreaded aftermath of the ACL tear

    • People usually feel or hear a pop when they tear their ACL and experience significant joint swelling within a couple of hours.
    • For athletes, the treatment of an ACL tear involves physical therapy, exercise or surgery, where the ACL is reconstructed using a piece of tendon harvested from the quadricep or hamstring muscles.
    • Under ideal conditions, recovery from an ACL tear takes nine to 12 months.

Greater risk for female athletes

    • The environments in which female athletes learn and play sport also contribute to the risk.
    • For example, at the 2021 NCAA March Madness, male athletes had access to a full gym, while female athletes were provided with a few light dumbbells and yoga mats.
    • However, the sporting environment hasn’t kept up, lacking resources, facilities and coaching tailored to meet the needs of female athletes.

Addressing the epidemic

    • This means a national professional league, pay and resource equity, investment in long-term welfare and prioritizing training opportunities for female coaches, trainers and medical staff.
    • There is also an urgent need to fund research focused on female health, injury prevention and long-term health.
    • Only through collective effort and a commitment to addressing all the root causes of ACL injuries in female athletes can we build a future where all athletes have an equal chance to excel in the beautiful game.

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Ohio State University, Antigen, Nanoparticle, AIM, MI, Solar cycle 1, CRS, American Society of Clinical Oncology, Clinical trial, DLT, Cancer, Bone marrow, Transplant, BMT, Chimera, Immunotherapy, Associate, Pleural effusion, Trial of the century, Șaeș, Acute myeloid leukemia, ASCO, City of Hope National Medical Center, AML, City, Influenza, MD, Patient, ECOG, Blood, Internal medicine, NEXI, PET/CT, Periodic breathing, Countersurveillance, Poster, Neoplasm, Phenotype, Society, Memory, Safety, Salvage therapy, Vaccine, Pharmaceutical industry, Medical imaging, Hematology

GAITHERSBURG, Md., June 05, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced results from its Phase 1/2 clinical trial of NEXI-001 in patients with relapsed/refractory acute myeloid leukemia (AML) post-allogeneic hemopoietic stem cell transplant (allo-HSCT). In this clinical trial to date, NEXI-001 is well tolerated with a favorable safety profile while eliciting an immune response to target antigens and a clinical effect in some patients. The data describing two patients from the dose escalation study of NEXI-001 are being presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago on Monday, June 5 at 8 AM in Hall A.

Key Points: 
  • “We have seen a clinical response maintained for seven months, which is an additional update from the data reported in our poster.
  • These data have established the ability of our AIM nanoparticles to expand healthy, multi-antigen-specific T cells with anti-tumor activity.
  • The data also show these T cells persist and maintain their memory phenotype at the site of tumor.
  • These data indicating both immunologic and clinical dose responses and observed durability in the patient at the higher dose support further clinical study of NEXI-001.

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014

Retrieved on: 
Monday, February 27, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Cancer, ATP, Monoclonal antibody, PD-1, Adenosine, Ascites, Pleural effusion, Patient, Trial of the century, TGF, TME, CD39, Medical imaging, Vaccine

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).
  • ES014 simultaneously targets the CD39-adenosine and TGF-β pathways, aiming to convert the immunosuppressive tumor microenvironment (TME) into an immune-friendly one.
  • ES014 simultaneously neutralizes TGF-β, leading to activation of T cells and blockade of Treg differentiation while avoiding or minimizing systemic immunotoxicity.
  • I am excited to move ES014 now to clinical study to investigate its safety and preliminary clinical signal in human,” shared Professor Lu.

Lunit and Agfa Announce Lunit INSIGHT CXR's Integration in Agfa's MUSICA® Workstation; Demonstration and Presentation to be Showcased at ECR 2023

Retrieved on: 
Monday, February 27, 2023
Pneumothorax, Congress, Patient safety, Mammography, ECR, Hospital, CXR, Workload, Pleural effusion, Patient, Abstract, Fluoroscopy, AI, Radiology, Pneumoperitoneum, European, Pathology, AUC, Communication, Tuberculosis, Medical imaging, Medical device, Agfa-Gevaert

SEOUL, South Korea, Feb. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) and Agfa Radiology Solutions today announced the integration of Lunit's AI solution for chest radiology, Lunit INSIGHT CXR, in the MUSICA® Workstation.

Key Points: 
  • SEOUL, South Korea, Feb. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) and Agfa Radiology Solutions today announced the integration of Lunit's AI solution for chest radiology, Lunit INSIGHT CXR, in the MUSICA® Workstation.
  • Agfa will showcase a demonstration of the integrated product at the upcoming European Congress of Radiology (ECR) 2023, to be held in Vienna, Austria, on March 1-5.
  • Lunit also announced that it will showcase a poster presentation highlighting Lunit INSIGHT CXR's ability to differentiate between normal and abnormal chest radiographs—one of 6 presentations Lunit will be delivering at ECR 2023.
  • Lunit will showcase a total of 6 abstracts at this year's ECR meeting, with 4 oral presentations and 2 poster presentations.

Global Liquid Biopsy Market Report 2022: Technique Brings a Revolution to Clinical Oncology - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Health, Oncology, CSF, Sample, Death, Prevalence, Diagnosis, Cancer, CAGR, Growth, Pleural effusion, Disease, Liquid biopsy, Neoplasm, Breast cancer, Technology, Application, Industry, Urine, Ageing, Research, Blood, Tobacco, Cerebrospinal fluid, USD, Population, Biomarker, Air pollution, Incidence, Workflow, Biopsy, Fine chemical, Medical imaging

The global liquid biopsy market was valued at USD 2,728.57 million in 2021, and during the forecast period, it is expected to expand at a CAGR of 13.77%.

Key Points: 
  • The global liquid biopsy market was valued at USD 2,728.57 million in 2021, and during the forecast period, it is expected to expand at a CAGR of 13.77%.
  • The primary reason propelling the growth of the liquid biopsy market is the rising incidence of cancer worldwide.
  • A further factor driving the growth of the liquid biopsy market in the years to come is the increasing use of liquid biopsy among prominent end users.
  • In this report, Global Liquid Biopsy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below: